Literature DB >> 18030443

[Adrenocortical carcinoma. Diagnostic work-up and treatment].

S Johanssen1, M Fassnacht, D Brix, A-C Koschker, S Hahner, H Riedmiller, B Allolio.   

Abstract

Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Preoperatively, a thorough hormonal work-up is mandatory, as the hormonal status may influence the perioperative management and may also provide marker hormones for monitoring of tumour recurrence. CT and MRI are equally sensitive and specific imaging tools for adrenal tumours. For discerning malignancy, assessment of the fat content of the tumour and contrast media wash-out after 10 min are of great value. Complete surgical resection of the tumour offers the only chance for cure. Open adrenalectomy via a flank or thoracoabdominal approach is the standard surgical technique. Intraoperative tumour spillage should be carefully avoided. Even after R0 resection, recurrence of the disease is frequent and regular follow-up for a minimum of 5 years is required. In advanced ACC, the treatment of choice is mitotane with or without cytotoxic chemotherapy (preferably after inclusion into the FIRM-ACT trial).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18030443     DOI: 10.1007/s00120-007-1578-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  26 in total

1.  Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography.

Authors:  S Leboulleux; C Dromain; G Bonniaud; A Aupérin; B Caillou; J Lumbroso; R Sigal; E Baudin; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-12-20       Impact factor: 5.958

2.  Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.

Authors:  Alfredo Berruti; Massimo Terzolo; Paola Sperone; Anna Pia; Silvia Della Casa; David J Gross; Carlo Carnaghi; Paolo Casali; Francesco Porpiglia; Franco Mantero; Giuseppe Reimondo; Alberto Angeli; Luigi Dogliotti
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

Review 3.  Management of patients with adrenal cancer: recommendations of an international consensus conference.

Authors:  D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

4.  Surveillance, epidemiology, and end results: incidence and mortality data, 1973-77.

Authors: 
Journal:  Natl Cancer Inst Monogr       Date:  1981-06

5.  5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.

Authors:  M Schlumberger; L Brugieres; C Gicquel; J P Travagli; J P Droz; C Parmentier
Journal:  Cancer       Date:  1991-06-15       Impact factor: 6.860

6.  A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.

Authors:  Jame Abraham; Susan Bakke; Ann Rutt; Beverly Meadows; Maria Merino; Richard Alexander; David Schrump; David Bartlett; Peter Choyke; Rob Robey; Elizabeth Hung; Seth M Steinberg; Susan Bates; Tito Fojo
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

7.  Management of the clinically inapparent adrenal mass ("incidentaloma").

Authors:  Melvin M Grumbach; Beverly M K Biller; Glenn D Braunstein; Karen K Campbell; J Aidan Carney; Paul A Godley; Emily L Harris; Joseph K T Lee; Yolanda C Oertel; Mitchell C Posner; Janet A Schlechte; H Samuel Wieand
Journal:  Ann Intern Med       Date:  2003-03-04       Impact factor: 25.391

8.  Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.

Authors:  R M Bukowski; M Wolfe; H S Levine; D E Crawford; R L Stephens; E Gaynor; W G Harker
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

Review 9.  Clinical review: Adrenocortical carcinoma: clinical update.

Authors:  Bruno Allolio; Martin Fassnacht
Journal:  J Clin Endocrinol Metab       Date:  2006-03-21       Impact factor: 5.958

10.  Surgical management, DNA content, and patient survival in adrenal cortical carcinoma.

Authors:  J E Lee; D H Berger; A K el-Naggar; R C Hickey; R Vassilopoulou-Sellin; R F Gagel; M A Burgess; D B Evans
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

View more
  3 in total

1.  [Adrenal tumors. Principles of diagnostics and operative treatment].

Authors:  A Gonsior; H Pfeiffer; D Führer; E Liatsikos; T Schwalenberg; J-U Stolzenburg
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

2.  Deficits in the management of patients with adrenocortical carcinoma in Germany.

Authors:  Sarah Johanssen; Stefanie Hahner; Wolfgang Saeger; Marcus Quinkler; Felix Beuschlein; Henning Dralle; Michaela Haaf; Matthias Kroiss; Christian Jurowich; Peter Langer; Wolfgang Oelkers; Martin Spahn; Holger S Willenberg; Uwe Mäder; Bruno Allolio; Martin Fassnacht
Journal:  Dtsch Arztebl Int       Date:  2010-12-17       Impact factor: 5.594

3.  Mechanism of cystogenesis in nephrotic kidneys: a histopathological study.

Authors:  Marijan Saraga; Katarina Vukojević; Vjekoslav Krželj; Zvonimir Puretić; Ivana Bočina; Merica Glavina Durdov; Stefanie Weber; Bernd Dworniczak; Danica Galešić Ljubanović; Mirna Saraga-Babić
Journal:  BMC Nephrol       Date:  2014-01-08       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.